# Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

> **NCT05530421** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 33 (estimated)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05530421
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-26
- **Primary completion:** 2028-03-26
- **Final completion:** 2030-03-26
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- Karyopharm Therapeutics Inc

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05530421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05530421, "Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT05530421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*